| Epithelial Neoplasm studied in …STUDIED_INderived10 of 8,636show all (up to 200) |
|---|
| → studied in | NCT00027326enrolling by invitation Collection of Blood and Urine From Patients Undergoing Radiation Therapy · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03976323Phase 3 · completed Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Unclassified Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04644770Phase 1 · active not recruiting A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04645160Phase 1/Phase 2 · recruiting Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Endometrial Mixed Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Endometrial Mixed Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05540925completed Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma · condition mapped ALIAS · 8,636 trials mapped (2,920 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05562830Phase 1/Phase 2 · recruiting A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) · condition mapped ONTOLOGY_EXACT · 8,636 trials mapped (2,920 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |